ABIVAX Société Anonyme (ETR:2X1)
Germany
· Delayed Price · Currency is EUR 95.40
-1.10 (-1.14%)
At close: Apr 28, 2026
ABIVAX Société Anonyme Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 69 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | 2X1 |
| Exchange | Deutsche Börse Xetra |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marc M. de Garidel | Chief Executive Officer |
| Didier Blondel | Chief Financial Officer |
| Patrick Malloy | Head of Investor Relations |